ArticleFrontiers in veterinary science2026
A retrospective study on cats with incompletely or marginally excised sarcomas treated with a bleomycin-only electrochemotherapy protocol: 66 cases.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Electrochemotherapy (ECT) is a novel therapy used as an effective and safe treatment modality for both cats and dogs with various tumor types. This retrospective study aimed to evaluate the disease-free interval (DFI) for cats with incompletely excised or marginally excised sarcomas treated with a bleomycin-only ECT protocol. Methods: A single institution retrospective evaluation was performed to identify cats as having undergone surgical removal of their sarcoma tumor followed by ECT from March 2015 to July 2024. In the absence of a standardized grading system for feline sarcomas, cats were stratified into high-grade and low-grade groups with primary emphasis on mitotic count. Median DFI was subsequently evaluated for each group. Results: A total of 66 cats were identified and were divided into a high-grade group, which consisted of 43 cats treated with an average of 2 ECT treatments, and a low-grade group, which consisted of 23 cats treated with a single ECT treatment. Intravenous bleomycin was injected followed by a subcutaneous injection of bleomycin along the surgical scar in a 2:1 ratio. The surgical scar, as well as 2 cm of tissue surrounding the scar was then treated with electroporation with the following parameters: 8 biphasic waveforms; pulses duration of 100 μs; pulse repetition frequency of 1 Hz and pulse amplitude 1,200 volts/cm. Median DFI for the cats in the low-grade group was not reached whereas the median DFI for cats within the high-grade group was 389 days. This was statistically significant between the two groups. Conclusion: This is the first study to evaluate a bleomycin-only ECT protocol in cats. Bleomycin-only ECT improved DFI compared to surgery alone for cats with incompletely or marginally excised sarcomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.